You are not authorized to access this page.
Search Within

Devanjan Sikder Sikder

Formats
  1. Meeting Abstract (10)
  2. Journal Article (3)
Groups
  1. Department of Medicine (13)
  2. Hematologic Malignancies, Division of (13)
  3. Adult Leukemia (12)
  4. Center for Hematologic Malignancies (12)
  5. Hematologic Malignancies Research (11)
  6. GSK Faculty (10)

More Groups

People
  1. Brigitte Senechal (13)
  2. Xiuyan Wang (13)
  3. Isabelle Riviere (10)
  4. Jae Park (10)
  5. Michel Sadelain (8)
  6. Maria Palomba (6)

More People

Years
  1. 2024 (1)
  2. 2023 (4)
  3. 2022 (3)
  4. 2021 (4)
  5. 2020 (1)
Publications
  1. Blood (7)
  2. Cancer Discovery (1)
  3. Clinical Pharmacology & Therapeutics (1)
  4. Cytotherapy (1)
  5. Hematological Oncology (1)
  6. Molecular Therapy - Methods & Clinical Development (1)

More Publications

Publishers
  1. American Society of Hematology (7)
  2. Nature Publishing Group (2)
  3. American Association for Cancer Research (1)
  4. Elsevier Science Ltd. (1)
  5. Massachusetts Medical Society (1)
  6. Wiley Blackwell (1)

Results (13)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Optimizing therapeutic outcome of CD19(T2)28z1XX chimeric antigen receptor (CAR) T in adult patients with large B-cell lymphoma through a quantitative medicine approach
    Meeting Abstract

    Dey, A.; Li, J.; Park, J. H.; Sellner, L.; Sundaresan, V.; Palomba, M. L.; Mansilla-Soto, J.; Senechal, B.; Wang, X.; Sikder, D. S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Role of cell therapy product characteristics in patient response to TAK-940 (CD19(T2)28z1xx chimeric antigen receptor (CAR) T): Biomarker analyses from a phase i study in adult patients with relapsed or refractory B-cell malignancies
    Meeting Abstract

    Sundaresan, V.; Senechal, B.; Wang, X.; Kashyap, S.; Tong, E.; Joshi, A.; Dash, A.; Sellner, L.; Chen, S.; McAvoy, D.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A phase I study of CD19-targeted 19(T2)28z1xx CAR T cells in adult patients with relapsed or refractory diffuse large B-cell lymphoma
    Meeting Abstract

    Park, J. H.; Palomba, M. L.; Devlin, S. M.; Valtis, Y. K.; Sikder, D. S.; Senechal, B.; Wang, X.; Cathcart, E.; Liotta, K.; Yu, A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Characterizing the relationship between cellular kinetics and response to support dosing recommendations for Cd19-targeted 19(T2)28z1xx cell therapy
    Meeting Abstract

    Li, J.; Singh, R.; Dey, A.; Sellner, L.; Liu, R.; Dash, A.; Park, J.; Palomba, M.; Mansilla-Soto, J.; Senechal, B.; more...
    Clinical Pharmacology & Therapeutics (2023)

    Fulltext@MSK | Save
  • A phase I study of CD19‐targeted 19(T2)28z1xx CAR T cells in adult patients with relapsed or refractory diffuse large B‐cell lymphoma
    Meeting Abstract

    Palomba, M. L.; Riviere, I.; Sikder, D. S.; Senechal, B.; Wang, X.; Cathcart, E. R.; Liotta, K.; Li, J.; Sellner, L.; Sadelain, M.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • A phase I study of CD19-targeted 19(T2)28z1XX CAR T cells in adult patients with relapsed or refractory diffuse large B-cell lymphoma
    Meeting Abstract

    Park, J. H.; Palomba, M. L.; Rivière, I.; Sikder, D. S.; Senechal, B.; Wang, X.; Bermudez, V. P.; Cathcart, E. R.; Liotta, K.; Joseph, J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • GPRC5D-targeted CAR T cells for myeloma
    Journal Article

    Mailankody, S.; Devlin, S. M.; Landa, J.; Nath, K.; Diamonte, C.; Carstens, E. J.; Russo, D.; Auclair, R.; Fitzgerald, L.; Cadzin, B.; more...
    New England Journal of Medicine (2022)

    Fulltext@MSK | Save
  • Autologous car T cell product from COVID-19-positive patient: Manufacturing and regulatory considerations
    Meeting Abstract

    Sikder, D.; Senechal, B.; Wang, X.; Geyer, M.; Riviere, I.
    Cytotherapy (2022)

    Fulltext@MSK | Save
  • Clinical manufacture of FT819: Use of a clonal multiplexed-engineered master induced pluripotent stem cell line to mass produce off-the-shelf CAR T-cell therapy
    Meeting Abstract

    Yuan, X.; Clarke, R.; Lai, Y. S.; Chang, C. W.; Yang, B. H.; Hsia, G.; Abujarour, R.; Lee, T.; van der Stegen, S.; Shaked, H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Phase I first-in-class trial of MCARH109, a G protein coupled receptor class C group 5 member D (GPRC5D) targeted CAR T cell therapy in patients with relapsed or refractory multiple myeloma
    Meeting Abstract

    Mailankody, S.; Diamonte, C.; Fitzgerald, L.; Kane, P.; Wang, X.; Sikder, D. S.; Senechal, B.; Bermudez, V. P.; Frias, D.; Morgan, J.; more...
    Blood (2021)

    Fulltext@MSK | Save